Lilly's obesity drug Mounjaro becomes India's top-selling drug by value in October

Core Insights - Eli Lilly's obesity drug Mounjaro has become the top-selling drug in India by value for October, achieving sales of 1 billion rupees ($11.38 million) [1] Company Summary - Mounjaro's sales performance indicates strong market acceptance and demand for obesity treatments in India [1] Industry Summary - The success of Mounjaro highlights the growing importance of obesity drugs in the pharmaceutical market, particularly in emerging markets like India [1]